NEW YORK (GenomeWeb) – Molecular diagnostics firm Diamir announced today that it has formed a research collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson, for the potential development of a microRNA-based companion diagnostic for neurodegenerative disease drug candidates.

Founded in 2009, Diamir is using its technology to develop assays that use blood-based miRNA signatures to diagnose neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and mild cognitive impairment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.